Trials / Terminated
TerminatedNCT01962896
A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Theodore Laetsch · Academic / Other
- Sex
- All
- Age
- 12 Months – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out if the combination of an mTOR inhibitor (sirolimus) with an EGFR inhibitor (erlotinib) is effective at treating relapsed or refractory germ cell tumors, and to find out what the side-effects of this regimen are.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erlotinib | |
| DRUG | Sirolimus |
Timeline
- Start date
- 2014-01-08
- Primary completion
- 2017-06-13
- Completion
- 2018-01-27
- First posted
- 2013-10-14
- Last updated
- 2019-02-26
- Results posted
- 2019-02-26
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01962896. Inclusion in this directory is not an endorsement.